NASDAQ:VRAY - ViewRay Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.50
  • Forecasted Upside: 57.23 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$4.77
▼ -0.07 (-1.45%)

This chart shows the closing price for VRAY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ViewRay Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VRAY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VRAY

Analyst Price Target is $7.50
▲ +57.23% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for ViewRay in the last 3 months. The average price target is $7.50, with a high forecast of $9.00 and a low forecast of $7.00. The average price target represents a 57.23% upside from the last price of $4.77.

This chart shows the closing price for VRAY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in ViewRay. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/22/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/22/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/21/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/19/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/18/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/17/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/11/2022B. RileyUpgradeNeutral ➝ Buy$7.00Medium
11/5/2021Piper SandlerBoost Price TargetOverweight$8.00 ➝ $9.00High
10/14/2021B. RileyInitiated CoverageNeutralHigh
6/25/2021Morgan StanleyUpgradeUnderweight ➝ Equal WeightHigh
5/7/2021GuggenheimUpgradeNeutral ➝ Buy$7.00High
3/26/2021BTIG ResearchUpgradeNeutral ➝ Buy$7.00High
1/12/2021Piper SandlerBoost Price TargetOverweight$4.00 ➝ $7.00Medium
1/6/2021Morgan StanleyBoost Price TargetUnderweight$2.00 ➝ $3.00N/A
11/6/2020Piper SandlerBoost Price TargetOverweight$3.50 ➝ $4.00High
10/28/2020B. RileyUpgradeNeutral ➝ Buy$2.75 ➝ $4.00High
6/23/2020OppenheimerReiterated RatingBuy$3.00Low
6/15/2020Cantor FitzgeraldInitiated CoverageBuy$3.00Medium
6/8/2020Cantor FitzgeraldReiterated RatingOverweightHigh
6/3/2020BTIG ResearchReiterated RatingHoldHigh
5/1/2020OppenheimerReiterated RatingBuy$4.50 ➝ $3.00High
4/30/2020BTIG ResearchReiterated RatingHoldHigh
4/28/2020GuggenheimDowngradeBuy ➝ NeutralHigh
3/27/2020Morgan StanleyDowngradeEqual Weight ➝ Underweight$2.00High
3/13/2020BTIG ResearchDowngradeBuy ➝ NeutralHigh
3/13/2020B. RileyLower Price TargetNeutral$5.00 ➝ $2.50High
3/13/2020MizuhoReiterated RatingBuy$7.00Low
12/10/2019MizuhoReiterated RatingBuy$9.00Low
12/4/2019B. RileyReiterated RatingBuy ➝ Neutral$9.00 ➝ $5.00High
12/3/2019GuggenheimReiterated RatingBuy$8.00High
12/3/2019MizuhoReiterated RatingBuy$9.00High
11/13/2019Cantor FitzgeraldReiterated RatingOverweightHigh
10/22/2019OppenheimerInitiated CoverageOutperform$7.00High
10/15/2019Piper Jaffray CompaniesSet Price TargetBuy$6.00Low
9/30/2019MizuhoSet Price TargetBuy$9.00Medium
9/13/2019Cantor FitzgeraldSet Price TargetBuy$6.00High
8/19/2019Northland SecuritiesReiterated RatingBuy$5.00Medium
8/12/2019Morgan StanleySet Price TargetHold$5.00Low
8/11/2019MizuhoReiterated RatingBuy$9.00High
8/9/2019Jefferies Financial GroupLower Price TargetBuy$14.00 ➝ $7.00Low
7/17/2019MizuhoReiterated RatingBuy$12.00Medium
6/18/2019Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$15.00High
5/28/2019Cantor FitzgeraldSet Price TargetBuy$13.00Low
5/2/2019Cantor FitzgeraldReiterated RatingBuy$13.00High
3/11/2019B. RileyReiterated RatingBuy ➝ Buy$13.75 ➝ $12.00Low
1/15/2019GuggenheimInitiated CoverageBuy$13.00High
12/20/2018Cantor FitzgeraldSet Price TargetBuy$13.00High
12/11/2018Morgan StanleyInitiated CoverageEqual ➝ Equal Weight$7.00High
12/6/2018Northland SecuritiesReiterated RatingBuy$20.00High
12/6/2018Cantor FitzgeraldReiterated RatingBuy$13.00Medium
10/18/2018Robert W. BairdInitiated CoverageOutperform ➝ Outperform$14.00High
10/3/2018Cantor FitzgeraldReiterated RatingBuy$13.00High
8/7/2018BTIG ResearchReiterated RatingBuy$14.00High
8/6/2018MizuhoReiterated RatingBuy$13.00High
7/3/2018Jefferies Financial GroupInitiated CoverageBuy$12.00High
5/11/2018Cantor FitzgeraldReiterated RatingBuy$13.00High
4/19/2018MizuhoReiterated RatingBuy$12.00High
2/8/2018B. RileyInitiated CoverageBuy ➝ Buy$13.50Low
1/9/2018MizuhoReiterated RatingBuy$12.00Medium
1/8/2018Cantor FitzgeraldSet Price TargetBuy$13.00Medium
1/5/2018Cantor FitzgeraldReiterated RatingOverweight ➝ OverweightHigh
11/17/2017Northland SecuritiesReiterated RatingBuy$10.00N/A
11/13/2017MizuhoReiterated RatingBuy$12.00N/A
11/3/2017MizuhoReiterated RatingBuy$12.00N/A
10/25/2017MizuhoReiterated RatingBuy$12.00N/A
10/12/2017MizuhoReiterated RatingBuy$12.00N/A
9/26/2017MizuhoReiterated RatingBuy$12.00Low
9/6/2017MizuhoInitiated CoverageBuy$12.00High
7/22/2017AegisReiterated RatingBuy$11.00High
6/29/2017Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$10.00Low
5/17/2017BTIG ResearchReiterated RatingBuy$10.00Medium
5/16/2017Northland SecuritiesReiterated RatingBuy$7.00High
5/16/2017AegisReiterated RatingBuy$11.00High
2/27/2017AegisReiterated RatingBuy$11.00N/A
2/27/2017Northland SecuritiesBoost Price TargetOutperform$6.00 ➝ $8.00N/A
2/6/2017AegisInitiated CoverageBuyN/A
(Data available from 1/17/2017 forward)

News Sentiment Rating

0.30 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/21/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
7/21/2021
  • 1 very positive mentions
  • 13 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
8/20/2021
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/19/2021
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/19/2021
  • 1 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 3 very negative mentions
11/18/2021
  • 2 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
12/18/2021
  • 3 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
1/17/2022

Current Sentiment

  • 3 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
ViewRay logo
ViewRay, Inc. designs, manufactures and markets magnetic resonance imaging (MRI) system. It develops MRIdian to address the limitations of existing external-beam radiation therapy technologies, and employs MRI-based technology to provide real-time imaging that defines the tumor from the surrounding soft tissue, and other critical organs, both before and during radiation treatment delivery. The company was founded by Dinara Akzhigitova in 2004 and is headquartered in Oakwood Village, OH.
Read More

Today's Range

Now: $4.77
Low: $4.60
High: $4.89

50 Day Range

MA: $5.45
Low: $4.71
High: $7.05

52 Week Range

Now: $4.77
Low: $3.79
High: $8.25

Volume

1,271,060 shs

Average Volume

1,384,220 shs

Market Capitalization

$785.82 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.81

Frequently Asked Questions

What sell-side analysts currently cover shares of ViewRay?

The following Wall Street sell-side analysts have issued research reports on ViewRay in the last year: B. Riley, BTIG Research, Guggenheim, Morgan Stanley, Piper Sandler, and Zacks Investment Research.
View the latest analyst ratings for VRAY.

What is the current price target for ViewRay?

4 Wall Street analysts have set twelve-month price targets for ViewRay in the last year. Their average twelve-month price target is $7.50, suggesting a possible upside of 57.2%. Piper Sandler has the highest price target set, predicting VRAY will reach $9.00 in the next twelve months. Guggenheim has the lowest price target set, forecasting a price of $7.00 for ViewRay in the next year.
View the latest price targets for VRAY.

What is the current consensus analyst rating for ViewRay?

ViewRay currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VRAY will outperform the market and that investors should add to their positions of ViewRay.
View the latest ratings for VRAY.

What other companies compete with ViewRay?

How do I contact ViewRay's investor relations team?

ViewRay's physical mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The company's listed phone number is (440) 703-3210 and its investor relations email address is [email protected] The official website for ViewRay is www.viewray.com.